SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies (ROLR) is experiencing a massive surge following its binding Letter of Intent with crypto.com/us to launch a US prediction markets product. This low-float stock is driving intense community discussion around a potential multi-day run and a significant short squeeze, though some caution against a possible pump and dump. Sentiment is highly speculative, with many anticipating continued upward momentum due to the crypto-adjacent hype.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial (RILY) is trending following the filing of its overdue Q3 2025 financial report, which has brought the company into NASDAQ compliance and showcased strong quarterly performance. This catalyst is fueling widespread community speculation of a massive short squeeze, with a significant portion of the float currently shorted, as traders anticipate a sharp price move and potential institutional buying. The ongoing discussion highlights RILY's perceived undervaluation and the pressure on short sellers as the company resolves its reporting issues.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing heightened investor interest and robust trading volume, driven by conviction in its Optical Interposer technology as a critical solution for high-speed, energy-efficient AI data center connectivity. The community is actively discussing the company's strategic partnerships and anticipating significant announcements, believing POET is poised for substantial growth in the rapidly expanding photonics sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is experiencing heightened attention driven by its presentation at the J.P. Morgan Healthcare Conference, where investors anticipate updates on new partnerships for its Matrix-M platform and a strategic outlook. The community buzzes with speculation about a potential short squeeze due to high short interest, while challenging management to secure decisive new collaborations beyond its existing COVID-19 vaccine.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending due to a widespread network outage affecting wireless services across the nation, leading to significant user frustration and calls for service reliability. The community is actively debating the cause, with speculation ranging from potential cyberattacks to underlying network issues, while questioning the stock's stability amidst discussions of customer retention challenges.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is a major talking point after recent discussions highlighted the increasing capital expenditures required for its AI infrastructure, including remarks about tech companies bearing their own data center electricity costs. Community sentiment is sharply divided, with some investors seeing a strong buying opportunity in its AI leadership, while others voice concerns over competition and potential impacts on profitability.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending as Bitcoin gains momentum, fueling speculation around upcoming legislative decisions like the Digital Asset Market CLARITY Act. While many bulls view COIN as a potential beneficiary of a more regulated crypto landscape and expanding product offerings, community sentiment is sharply divided, with deep frustration voiced over its perceived underperformance compared to broader crypto market moves.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is trending intensely amid a powerful rally, driven by discussions around surging physical demand, significantly higher silver prices in Asian markets, and reports of the US Mint halting sales. Community members are passionately debating whether this parabolic move is a sustainable repricing due to industrial demand and supply deficits or a speculative bubble poised for a sharp correction, with many anticipating continued upward momentum or a significant pullback.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company (ABAT) is trending with strong bullish sentiment driven by rising lithium prices and its prominent role in critical mineral discussions, including leadership engagement at a G7 summit. The community is highlighting technical buy signals, the significance of its battery recycling operations, including updates on the Moss Landing contract and claystone plant, and anticipating catalysts such as DOE grants and EXIM financing for future expansion. This positions ABAT as a key domestic player in the evolving battery and critical minerals sector.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively discussed amidst escalating geopolitical developments in the Middle East and notable sector rotation out of key tech names, sparking significant intraday volatility. Despite these mixed signals and increased market fear, many in the community continue to advocate for buying dips, reflecting persistent bullish sentiment. This dynamic keeps broader market direction a central talking point as participants assess global stability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus Armata Pharmaceuticals...

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?

Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

<ul class="summary-bullets"><li>The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus bacteremia, with no relapses reported.</li><li>H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.</li><li>Retail traders flooded Stocktwits with bullish posts after the record rally, with some predicting further gains while others expected a share offering.</li></ul>Shares of Armata Pharmaceuticals surged to a record high on Wednesday after the company reported encouraging Phase 2a results for its experimental bacteriophage therapy, AP-SA02, in patients with complicated Staphylococcus aureus bacteremia (SAB), a serious and often life-threatening bloodstream infection.The stock logged its best session on record on Wednesday, surging 103% to close at $7.05, and fell 16% in after-hours trading as investors took profits following the steep rally.Promising Results In Early-Stage TrialThe findings show for the first time, in a randomized trial, that intravenous phage therapy can be efficacious for S. aureus bacteremia.&nbsp;The diSArm study showed that patients treated with AP-SA02 in addition to the best available antibiotic therapy had an 88% clinical response rate at day 12, compared with 58% for placebo. No patients treated with AP-SA02 relapsed or were non-responsive, versus approximately 25% of patients who received&nbsp;a placebo.A total of 42 patients were enrolled in the trial, and about 38% of the cases had infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Armata said that the treatment was well-tolerated with no serious adverse events associated with the drug.The company is looking to move AP-SA02 into a Phase 3 trial in 2026, based on these results, subject to regulatory input from the U.S. Food and Drug Administration.Analyst ViewH.C. Wainwright reaffirmed its ‘Buy’ rating and $9 price target on Armata, representing a 28% upside from the company’s last close. The brokerage said the results, along with supporting in vitro data, provide “strong evidence for the efficacy of its core therapeutic strategy.” The firm said the data support moving the bacteriophage therapy into a pivotal late-stage study next year.Multi-Phage Cocktail Shows Broad Efficacy&nbsp;Armata said AP-SA02, a fixed cocktail of multiple bacteriophages, showed consistent efficacy against both MRSA and methicillin-sensitive S. aureus (MSSA) and was linked to faster infection clearance and shorter hospital stays. The company received $26.2 million in funding from the U.S. Department of Defense through the Medical Technology Enterprise Consortium to support the diSArm study.Stocktwits Traders See Potential Stock Offering&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 26,200% surge in 24-hour message volume.One user said they expected the company to announce a share offering following the surge in its stock price.<stembedurl>https://stocktwits.com/FredDurst/message/633328173</stembedurl>Another user, however, struck an optimistic tone, predicting that the stock could double in value the next day.<stembedurl>https://stocktwits.com/Lifeinlight/message/633324622</stembedurl><a href="https://stocktwits.com/symbol/ARMP">Armata’s stock</a> has&nbsp;rocketed 281% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Armata Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Armata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In

H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.

Equity

Are Medical Stocks Lagging  Armata Pharmaceuticals (ARMP) This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

ARMP
Armata Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARMP News

ARMPArmata Pharmaceuticals Inc